Levetiracetam in the treatment of idiopathic generalized epilepsies

Epilepsia

Volumn 46, Issue SUPPL. 9, 2005, Pages 154-160

  Grünewald, Richard ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Children; Idiopathic generalized epilepsy; Juvenile myoclonic epilepsy; Levetiracetam

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; ANTICONVULSIVE AGENT; BICUCULLINE; BRADYKININ; CALCIUM; CYTOCHROME P450; ETHOSUXIMIDE; ETIRACETAM; GLYCINE; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID; ORAL CONTRACEPTIVE AGENT; PENTETRAZOLE; PHENOBARBITAL; PICROTOXIN; PIRACETAM; PLACEBO; UCB 30889; VALPROIC ACID; DRUG DERIVATIVE;

ABSENCE; AGGRESSION; ANTICONVULSANT ACTIVITY; ANXIETY; ASTHENIA; BEHAVIOR DISORDER; CALCIUM CURRENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENERALIZED EPILEPSY; HAIR LOSS; HEADACHE; HUMAN; IDIOPATHIC DISEASE; INTRACTABLE EPILEPSY; IRRITABILITY; LEARNING DISORDER; MENTAL INSTABILITY; MONOTHERAPY; MOOD CHANGE; MOOD DISORDER; MYOCLONUS SEIZURE; NONHUMAN; PARADOXICAL DRUG REACTION; PARANOID PSYCHOSIS; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RASH; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; VERTIGO; VIOLENCE; WEIGHT CHANGE; WEIGHT GAIN; ADULT; ANIMAL; ARTICLE; CHILD; DISEASE MODEL; FEMALE; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTICONVULSANTS; CHILD; DISEASE MODELS, ANIMAL; EPILEPSY, GENERALIZED; FEMALE; HUMANS; PIRACETAM; TREATMENT OUTCOME;

EID: 32944476207     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00329.x     Document Type: Review

References (72)

1. Levetiracetam summary of product characteristics. UCB Pharma, February 2004.
2. French JA, KannerAM,Bautista J, et al. American Academy of Neurology Therapeutics and Technology Assessment Subcommittee, American Academy of Neurology Quality Standards Subcommittee, American Epilepsy Society Therapeutics and Technology Assessment Subcommittee, American Epilepsy Society Quality Standards Subcommittee. Efficacy and tolerability of the newantiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. [erratum appears in Epilepsia, 2004;45(11):1299]. Epilepsia 2004;45(5):410-23.
3. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 1995;67:351-84.
4. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43:707-24.
5. May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003;25:690-9.
6. Gidal BE, Baltes E, Otoul C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res 2005
7. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 2002;48:217-9.
8. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam appears to act via a specific site in CNS membranes. Eur J Pharmacol 1995;286:137-46.
9. Fuks B, Gillard M, Michel P, et al. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol 2003;478:11-9.
10. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Nat Acad Sci U S A 2004;101:9861-6.
11. Gu J, Lynch BA, Anderson D, et al. The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci 2004;19:334-45.
12. Husum H, Bolwig TG, Sanchez C, et al. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1 and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav 2004;5:204-15.
13. Pisani A, Bonsi P, Martella G, et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004;45:719-28.
14. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001;306:5-8.
15. 2+ transients and epilpetiform potentials in hippocampal neurons. NeuroReport 2003;14(3): 471-75.
16. Rigo J-M, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glucine-gated currents. Br J Pharmacol 2002;136:659-72.
17. 2+]iincrease induced by ATP and bradykinin in PC12 cells. J Pharm Exp Ther 2005;313:720-30.
18. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45:661-71.
19. Gower AJ, Noyer M, Verloes R, et al. UCB L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222:193-203.
20. Gower AJ, Hirsch E, Boehrer A, et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995;22:207-13.
21. Marescaux C, Micheletti C, Vergnes M, et al. A model of chronic spontaneous petit mal-like seizures in the rat: comparison with pentylenetetrazol-induced seizures. Epilepsia 1984;25:326-31.
22. Mazarati AM, Baldwin R, Klitgaard H, et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 2004;58:167-74.
23. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 2001;3:379-403.
24. Manning JP, Richards DA, Bowery NG. Pharmacology of absence epilepsy. Trends Pharmacol Sci 2003;24:542-9.
25. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicentre, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-83.
26. Cereghino JJ, Biton V, Abou-Khalil B, et al. and the United States Levetiracetam Study Group. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42.
27. Shorvon SD, Löwenthal A. Multicenter double-blind randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179-86.
28. Verdru P, Wajgt A, Delgado JS, et al. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures. Epilepsia 2005;46(suppl 6):56.
29. Data on file. UCB Pharma.
30. Kasteleijn-Nolst Trenité DGA, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue levetiracetam. Epilepsy Res 1996;25:225-30.
31. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9:80-7.
32. Reis J, Knake S, Hamer HM, Oertel WH et al. Efficacy and tolerability of levetiracetam in the treatment of focal and generalized epilepsy. 12th Meeting of the European Neurological Society, Berlin, Germany, June 2002. Abstract P281.
33. Beran R,Weber S, Linto J. A pilot study of levetiracetam in patients with generalized epilepsy. Epilepsia 2002;43(suppl 8):153. Abstract P486.
34. Meencke H, Straub HB, Dehnicke CH, et al. Levetiracetam in idiopathic generalized epilepsies. Epilepsia 2002;43(suppl 8):153.
35. Cohen J. Levetiracetam monotherapy for primary generalized epilepsy. Seizure 2003;12:150-3.
36. Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalized epilepsy. Seizure 2003;12:617-20.
37. Covanis A, Katsalouli M. Levetiracetam monotherapy in generalized epilepsy and photosensitivity. Epilepsia 2003;44(suppl 8):80.
38. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalized epilepsies. Seizure 2004;13:475-7.
39. Kasteleijn-Nolst Trenite DG, Hirsch E. Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord 2003;5(suppl 1):S39-S44.
40. Covanis A, Stodieck SR,Wilkins AJ. Treatment of photosensitivity. Epilepsia 2004;45(suppl 1):40-5.
41. Panayiotopoulos CP. Idiopathic generalized epilepsies. In: Panayiotopoulos CP, ed. The epilepsies: seizures, syndromes and management. Oxford: Bladon Medical Publishing, 2005:271-348.
42. Greenhill L, Betts T, Smith K. Effect of levetiracetam on resistant juvenile myoclonic epilepsy. Epilepsia 2002;43(suppl 7):179.
43. Resor SR, Resor LD. Levetiracetam monotherapy in the treatment of convulsive seizures in juvenile myoclonic epilepsy. Presented at the 54th Annual Meeting of the American Academy of Neurology, April 13-20, 2002; Denver, CO.
44. Jongsma M, Janssen G, Engelsman M, et al. Promising results of levetiracetam in juvenile myoclonic epilepsy. Epilepsia 2002;43(suppl 8S):153.
45. Czapinski PP, Czapinska EM. The effectiveness of levetiracetam in drug-resistant juvenile myoclonic epilepsy. Epilepsia 2004;45(suppl 3):141.
46. La Neve A, Boero G, Specchio N, et al. Levetiracetam is effective in juvenile myoclonic epilepsy. Epilepsia 2004;45(suppl 3): 141.
47. Gelisse P, Crespel A, Genton P, Baldy-Moulinier M. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003;107:302-3.
48. Van Zandijcke M. Treatment of myoclonus. Acta Neurol Belg 2003;103:66-70.
49. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003;44(suppl 11):27-37.
50. Crest C, Dupont S, LeGuern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004;62:640-3.
51. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000;2:209-12.
52. Frucht SJ, Louis ED, Chuang C, et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-4.
53. Krauss GL, Bergin A, Kramer RE, et al. Suppression of posthypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001;56:411-2.
54. Schauer R, Singer M, Saltuari L, et al. Suppression of cortical myoclonus by levetiracetam. Mov Disord 2002;17:411-5.
55. Lagae L, Buyse G, Deconinck A, et al. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 2003;7:123-8.
56. Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 2004;13:142-5.
57. Weintraub D, Buchsbaum R, Spencer HT, et al. Tolerability of levetiracetam in 516 patients; analysis by dose and serum concentration. Epilepsia 2004;45(suppl 3):68.
58. Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001;42:1611-3.
59. Youroukos S, Lazopoulou D, Michelakou D, et al. Acute psychosis associated with levetiracetam. Epileptic Disord 2003;5:117-9.
60. Nakken KO, Eriksson AS, Lossius R, et al. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003;12:42-6.
61. Dinkelacker V, Dietl T, Widman G, et al. Aggressive behaviour of epilepsy patients in the course of levetiracetam add-on therapy; report of 33 mild to severe cases. Epilepsy Behav 2003;4:537-47.
62. Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003;12:131-5.
63. Huber B, Bommel W, Hauser I, et al. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure 2004;13:168-75.
64. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004;13:55-7.
65. Rugino TA, Samsock TC. Levetiracetam in autistic children. J Dev Behav Pediatr 2002;23:225-30.
66. Brodtkorb E, Klees TM, Nakken KO, et al. Levetiracetam in adult patients with and without learning disability: focus on behavioural adverse effects. Epilepsy Behav 2004;5:231-5.
67. Kapoor P, McCabe P, Kothari MJ. Levetiracetam induced polyneuropathy: a case report. Electromyography & Clinical Neurophysiology 2005;45(1):15-7.
68. Kimland E, Hojeberg B, von Euler M. Levetiracetam-induced thrombocytopenia. Epilepsia 2004;45(7):877-8.
69. Isoherranen N, Spiegelstein O, Bialer M, et al. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyloxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia 2003;44:1280-8.
70. Gidal BE, Sheth RD, Magnus L, et al. Levetiracetam does not alter body weight: analysis of randomised, controlled clinical trials. Epilepsy Res 2003;56:121-6.
71. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002;43:697-702.
72. Barrueto F Jr,Williams K, Howland RS et al.Acase of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol 2002;40:881-4.